<DOC>
	<DOCNO>NCT00025168</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine irinotecan , work different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy radiation therapy treat patient locally advance , unresectable pancreatic cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Locally Advanced Unresectable Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine time progression , local control , survival patient locally advance , unresectable pancreatic cancer treat induction gemcitabine irinotecan follow gemcitabine concurrent radiotherapy . OUTLINE : Patients receive induction gemcitabine IV 30 minute irinotecan IV 90 minute day 1 8 . Treatment repeat every 3 week 2 course absence disease progression unacceptable toxicity . Within 2 week complete induction chemotherapy , patient receive gemcitabine IV 30-60 minute day 1 , 4 , 8 , 11 , 15 , 18 , 22 , 25 , 29 , 32 . Patients undergo concurrent radiotherapy 5 day week 5.5 week . Patients follow every 8 week 6 month every 3 month 1.5 year . PROJECTED ACCRUAL : Approximately 60-120 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advanced pancreatic cancer Regional ( peripancreatic ) lymph node involvement allow Clinically surgically stag consider unresectable inoperable PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 6 month Hematopoietic : Granulocyte count least 1,500/mm3 Hemoglobin least 10 g/dL Platelet count least 100,000/mm3 Hepatic : Not specify Renal : Creatinine great 2.0 mg/dL Other : Not pregnant Fertile patient must use effective contraception No concurrent prior malignancy within past 2 year except nonmelanoma skin cancer situ carcinoma cervix breast No serious medical psychiatric illness would preclude give informed consent limit survival le 2 year PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent anticancer immunotherapy Chemotherapy : No prior chemotherapy No concurrent anticancer chemotherapy Endocrine therapy : No concurrent anticancer hormonal therapy Radiotherapy : No prior abdominalpelvic radiotherapy No concurrent anticancer radiotherapy Surgery : See Disease Characteristics At least 3 week since prior open abdominal surgery More 10 day since prior laparoscopy Other : No concurrent investigational drug No concurrent participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
</DOC>